News

RIVANNA® Announces Alliance With Tri-anim Health Services

RIVANNA®, developers of world-first, imaging-based medical solutions, announced they have entered into a partnership with Tri-anim Health Services, a specialty distributor of respiratory, anesthesia, and critical-care supplies, to represent and distribute the Accuro® portfolio of products in the United States.
RIVANNA announced a partnership with Tri-anim Health Services

Tri-anim is a natural distribution choice for RIVANNA as they provide effective and efficient patient care solutions, including innovative and proven specialty anesthesia products and consumables to support the vital role of the anesthesia provider.

Will Mauldin, Ph.D., co-founder, and CEO of RIVANNA, commented, “We worked together to establish this strategic partnership, and are excited to begin an alliance with Tri-anim due in part to their specialty anesthesia focus and clinical expertise. This milestone demonstrates an increasing opportunity for Accuro sales in the anesthesia market, and we are pleased to gain momentum across the United States. Accuro’s increased national expansion and continuing worldwide market adoption indicate RIVANNA’s success and the progression of our ongoing mission to elevate the standard of care.”

The Accuro spinal navigation system is designed to improve the efficiency of spinal needle guidance procedures using groundbreaking technology, including Multi-Frequency BoneEnhance® Image Reconstruction, which provides enhanced visualization of lumbar and thoracic bony anatomy, and SpineNav3D™AI-Based Spine Recognition, which provides automated identification of spinal midline, epidural space, and depth during lumber neuraxial anesthesia. This technology also supports real-time thoracic paramedian neuraxial procedures and prescribes a “needle-track” towards the interlaminar space. Relying on automated SpineNav3D™ technology, Accuro enables users with even minimal ultrasound experience to navigate the lumbar and thoracic spine and identify relevant landmarks used to compute, visualize and pinpoint the optimal needle insertion point.

Tom Metcalf, President of Tri-anim Health Services, said, “The Tri-anim team is thrilled to introduce this groundbreaking technology to an expanding market supporting spinal needle guidance procedures in the U.S., as it underpins Tri-anim’s vision to offer the most effective products and solutions to our customers. The Accuro is clinically proven to increase first-attempt success rates, especially with challenging patient anatomy, and will help anesthesia providers improve their efficiency and elevate their standard of care.”

Recent News

04/29/2025

ODU breaks ground on $184M biosciences building

Old Dominion University on Monday broke ground on the biggest capital construction project in the 95-year-old university’s history — a new biological sciences building. The planned five-story, 162,586 square-foot building will be located on ODU‘s campus in Norfolk, near the university’s Oceanography and Mills Godwin Life Sciences buildings. ODU spokesperson Jonah Ross Grinkewitz said the

04/29/2025

Compremium AG Appoints Dr. Kolaleh Eskandanian to Lead New Division of Pediatrics and Special Populations

Dr. Eskandanian, a global leader in pediatric innovation, joins Compremium from Children’s National Hospital in Washington, D.C., where she most recently served as Vice President and Chief Innovation Officer, Executive Director of the Sheikh Zayed Institute for Pediatric Surgical Innovation, and founding executive of Innovation Ventures. Her appointment marks a strategic milestone in Compremium’s expansion

04/24/2025

SSI Diagnostica Group Acquires Breath Test Maker Gulf Coast Scientific

Infectious disease diagnostics firm SSI Diagnostica Group said on Thursday that it has acquired Florida-based breath testing firm Gulf Coast Scientific for an undisclosed sum. Gulf Coast Scientific is a developer of urea breath tests for Helicobacter pylori infection, which is associated with conditions including chronic gastritis and gastric cancer. SSID Group said that the